CHA Hollywood Presbyterian Medical Center Opens First Dedicated Hospital-Based Ophthalmic Operating Room in Los Angeles County

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

Today CHA Hollywood Presbyterian Medical Center (CHA HPMC), a hospital that is a member of CHA Health Systems, a global network providing a full spectrum of dynamic healthcare services, announced the opening of a state-of-the-art ophthalmic surgery suite as part of the hospital’s Southern California Eye Institute. The new hospital-based ophthalmic operating room is the first hospital-based facility dedicated to eye surgery in the Los Angeles area.

Regarding the hospital-based ophthalmic operating room, Rohit Varma, MD, MPH, director of Southern California Eye Institute said, “As a team, we’ve taken bold steps to create a premier surgical suite that will offer the latest advancements and technology while focusing on patient experience and outcomes.”

The surgical suite is designed to create a seamless experience for patients and families. The operating rooms will be fully equipped with new state-of-the-art laser only cataract technology by early 2020, which will enable more precise intraocular implant measurements. The dedicated operating room will also have its own scheduling system, enabling convenient, faster scheduling for patients and community ophthalmologists.

“We’re very excited to finally have two ophthalmology-exclusive operating rooms available for patients and healthcare providers,” said Jacob Reznik, MD, a cataract and refractive surgery specialist who will oversee the surgery suite. “We will work closely with our colleagues and CHA HPMC physicians to continue building upon this center of excellence in ophthalmic surgery.”

With the laser-assisted cataract surgery technology, ophthalmic surgeons will be able to perform minimally invasive surgeries. New suite will also enable the performance of advanced glaucoma surgical tubes and trabeculectomies including XenGel implantation, microincisional glaucoma surgery including iStent, Hydrus, Kahook dual-blade (KDB) OMNI, and micropulse laser. Advanced retinal procedures will include small incision sutureless vitrectomy, epiretinal membrane surgery, and advanced diabetic disease procedures. Innovative oculofacial plastic surgery procedures will include ptosis (droopy eyelid), blepharoplasty (excess skin), ectropion (eyelid turning out), entropion (eyelid turning in), eyelid tumors, thyroid eye disease, tearing problems, facial trauma, and orbital tumors. The cutting edge therapy using the newest advanced technology will reduce surgical times and enable quick recovery for patients to return to their daily activities quickly.

“We are on a continual mission to create better ways — and embarked on a $400 million master plan slated for completion by 2021. We are making huge investments in the facility to develop Centers of Excellence, innovative technology, and people to better serve our Los Angeles community and be the medical center of the future,” said Robert Allen, CHA Hollywood Presbyterian Medical Center president and chief executive officer.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles